daniele biasci

IPO on the Nasdaq is so much fun! #ipo #absci

@ilyasut People deserve to know why.

I deeply regret my participation in the board's actions. I never intended to harm OpenAI. I love everything we've built together and I will do everything I can to reunite the company.

Our Mathematical and Computational Methods in Cancer and Biology Symposium has started. Thank you to our opening speakers: Simon Tavaré, Jeannette Wing, Michael Waterman, and Anil Rustgi.

@noriko_amanopat Grazie Noriko. Its honestly a lot of fun!!

@daniele_1981 Ok, I’m starting to feel like your groupie 😅. I’m done with likes for you for the day… Congratulations though!!!!

IPO on the Nasdaq is so much fun! #ipo #absci

@CAonline @AmerCancerCEO @AmerCancerCMSO @AmericanCancer @ACS_Research Time for the FED to raise interests rates. Clearly hyperinflation is already here!

CA is pleased to announce that the Impact Factor for 2020 has increased to 508.7. We express our sincerest thanks to our editors, authors, reviewers, and readers for helping us achieve this significant milestone.

Congrats @DenizKural, James Sietstra, @Daniele_1981 & team! @TotientBio uses AI to accelerate drug discovery. Absolutely rooting -- your success at @AbSciBio makes the world better. It's the first exit of @TauVentures that @SanjayRao and I started in 2019. prnewswire.com/news-releases/…

We started Totient four years ago with the idea of making fully human antibodies from tertiary lymphoid structures. I am delighted to announce that #Totient was acquired by #AbSci today! prnewswire.com/news-releases/…

Totient's manuscript describing the first large scale study of antigens recognized by fully human intratumoral antibodies is now available on bioRxiv. biorxiv.org/content/10.110…

Excited to be presenting at the Kennedy Institute in Oxford. I will be sharing some new data on FDCSP+ fibroblasts and immunotherapy response. #Immunotherapy #Immunology

Your wish is my command @MalcolmNance, and thanks for fighting the good fight! #TheForceIsSTRONGWithJoe

A new clinical trial shows it may be possible to expand cancer immunotherapy to help more patients in the future. Computational immunology analysis was led by Daniele Biasci, CAMS Fellow at MRC Tox Unit. Here's the link to the press release from CRUK cruk.cam.ac.uk/2020/11/02/giv…

This was a very nicely planned phase 1 trial, with biopsies collected before and during therapy, and RNAseq data from both. The amount of information we got from it was incredible. With scRNAseq going mainstream, things will only get better...

# Researchers Find Effective Immunotherapy Against Non-Responsive Cancer Types Researchers: @daniele_1981, @JanowitzTobias Institutes: @Cambridge_Uni, @CRUKCamCentre, @CSHL, @CRUK_CI Publication: @PNASNews #nes #cancer #CancerResearch #MedTwitter atomstalk.com/news/effective…

Finally published! pnas.org/content/early/…

@InesBarroso4 Seriously??

If that was really the advice given “women should deepen their voice” then it is completely unacceptable advice. Shocking really and 😞 #WomenInSTEM #athenaswan #ThisisNotOK

Totient partnered with Integral Molecular to screen antibodies from human tumors against one of the world's largest (6000!) collection of native human membrane proteins. This is going to be really cool... integralmolecular.com/totient-levera…

@MaggieAstor hi Maggie, I am not trump fan but your article contains a big error: the Regeneron cocktail is well into phase 3 newsroom.regeneron.com/news-releases/…

@Margolis73 They reached out to clarify the article.

@Margolis73 I guess they both have a lot of “room for improvement”...

Incredibly, Fox News is calling “polyclonal antibodies” the two monoclonal antibodies administered to President Trump. We really need to do better: correct scientific communication makes everyone safer. #immunology #antibodies #covid19pandemic #foxnews foxnews.com/health/what-ar…

To Fox News credit, they reached out already to clarify the issue.